Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO-Reference-Cited by-同舟云学术

Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO

Published:2020-08-31 Issue:6 Volume:39 Page:2049-2054
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Soliman Mohamed G.^ORCID,El-Abd Shawky A.,Tawfik Ahmed M.,Radwan Mohamed H.,El-Abd Ahmed S.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-020-03425-3.pdf

Reference30 articles.

1. Wang H, Chang Y, Liang H (2017) Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pak J Med Sci 33(4):988–992

2. Abrams P et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49

3. Masumori N et al (2010) The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol. https://doi.org/10.1155/2010/205251

4. Witjes WP et al (1997) The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother. J Urol 157(4):1295–1300

5. Kaplan SA et al (2013) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63(1):158–165

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comination pharmacotherapy of lower urinary tract symptoms;Urologie pro praxi;2024-03-15

2. Medical Advancements in Benign Prostatic Hyperplasia Treatments;Current Urology Reports;2024-03-07

3. Safety and efficacy of an α₁‐blocker plus mirabegron compared with an α₁‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta‐analysis;Neurourology and Urodynamics;2024-01-30

4. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia;Expert Opinion on Pharmacotherapy;2023-07-21

5. Updates of Overactive Bladder in Pediatrics;International Neurourology Journal;2023-03-31